总体来看，港股年内涨幅超过40%的生物医药类ETF有17只，汇添富、银华、华泰柏瑞、万家、广发、 富国基金旗下相关产品年内涨幅均超55%。 今年以来，国产创新药行情火爆远超市场预期。 数据显示，截至6月9日，万得创新药指数年内涨近30%，而港股创新药指数更是飙升近60%，创下近年 新高。 | 陸号 | 证券代码 | 证券简称 | 区间涨跌幅 | | | --- | --- | --- | --- | --- | | | | | [区间首日] 本年初 [区间롭日] 2025-6-9 | | | | | | [車位] %] | | | | 866076.WI | 万得创新药指数 | | 27.6209 | | 2 | 931787CNY00.CSI | 港股创新药(CNY) | | 56.4975 | 值得一提的是，本轮"吃药"行情与过往医药牛市存在显著差异： 涨幅龙头集中于创新药企业，且港股表现尤为强劲。南下资金持续涌入带来的估值抬升，使得重仓港股 的医药主题QDII基金表现亮眼。 截至6月9日，跨境ETF涨幅榜中，年内涨超40%的基金均为与生物医药主题相关基金： | | | | 售股生物医药类ETF年内核心情 ...

Core Viewpoint - The Chinese innovative drug sector is experiencing a resurgence, driven by recent approvals of new drugs, increased market activity, and favorable policy changes, indicating a new growth cycle for the industry [1][2][16]. Group 1: Market Activity - On May 29, the National Medical Products Administration approved 11 innovative drugs, with 10 from listed companies, leading to a surge in stock prices and significant market interest [1]. - Following the approvals, 53 stocks hit the daily limit up in the A-share market, and over 200 million yuan flowed into innovative drug ETFs in Hong Kong over the past 20 trading days [1][2]. - The innovative drug sector, which had been quiet for two years, is now seeing renewed interest from investors, with venture capitalists starting to push more projects for investment decisions [2]. Group 2: Funding Trends - The first quarter of 2025 saw over 20 billion yuan in financing for the innovative drug sector, with at least 19 financing events occurring, indicating a robust recovery in investment [3][4][5]. - Major financing rounds included significant investments in companies focusing on various therapeutic areas, including immunotherapy and gene therapy, showcasing a diverse interest from capital [4]. Group 3: Product Development - In the first five months of this year, over 20 class 1 innovative drugs were approved, marking a record for the past five years [6][7]. - The approval rate for new drugs has significantly increased since the implementation of the new drug registration management measures in 2020, with approvals rising from single digits in previous years to over 30 in recent years [8]. Group 4: Policy Environment - The regulatory environment for innovative drugs in China is continuously improving, with recent reforms aligning more closely with international standards, enhancing the credibility of clinical trial data [11][12]. - The government has implemented a comprehensive support system for innovative drugs, including payment reforms and a multi-layered insurance system, which is expected to facilitate market access and improve commercialization prospects [13][14][15]. Group 5: Future Outlook - The innovative drug sector is poised for a new growth cycle, supported by clinical breakthroughs, international collaborations, and favorable policies, indicating a potential "golden period" for the industry [16].

Group 1 - The Hang Seng Medical Index ETF has shown active trading with a turnover of 14.61% and a transaction volume of 40.57 million yuan, indicating a vibrant market activity [3] - Over the past two weeks, the Hang Seng Medical Index ETF has experienced a significant growth in scale, increasing by 4.21 million yuan, ranking in the top third among comparable funds [3] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 27.7 times, which is at a historical low, being below 91.86% of the time over the past three years [3] Group 2 - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 57.95% of the index, with notable companies including Innovent Biologics, BeiGene, and WuXi Biologics [3] - Recent government policies aim to enhance and improve public health services, including adjustments to the basic medical insurance drug list and the introduction of innovative drug lists for commercial health insurance [3] - Industry experts anticipate that the medical innovation sector is entering a harvest period, with a clear trend of performance and valuation recovery expected in the second half of the year [3] Group 3 - Yangtze Securities highlights that favorable domestic policies are emerging to encourage high-quality innovation, which may drive rapid growth in corporate performance [4] - The valuation levels of domestic innovative drugs are low, with some products showing potential to be the best in their class globally, suggesting a positive outlook for international market expansion [4] - Investors without stock accounts can access investment opportunities in the Hong Kong medical sector through the Hang Seng Medical Index ETF linked fund (018433) [4]

Group 1 - The article emphasizes the continuous recommendation of innovative drugs and an increased focus on the Pharma sector, highlighting the high demand for innovative drugs and the potential for revaluation of the Pharma sector [1][2] - Recent business development (BD) activities indicate a strong demand from multinational pharmaceutical companies for high-quality innovative drug assets from China, suggesting a robust logic for innovative drugs going global [2] - The performance of the A-share pharmaceutical sector in the first week of June 2025 was on par with the overall market, with specific sub-sectors like chemical raw materials and chemical preparations showing relatively better performance [3] Group 2 - In the first week of June 2025, the Hong Kong pharmaceutical sector outperformed the market, while the US pharmaceutical sector performed similarly to the market [3] - The current relative premium rate of the pharmaceutical sector compared to the entire A-share market is at a normal level of 86.84% as of June 6, 2025 [3]

Core Viewpoint - The current "medication" market rally is distinct from previous ones, with leading gains concentrated in innovative pharmaceutical companies, particularly strong performance in the Hong Kong stock market [1][2] Group 1: Market Performance - On June 9, both Hong Kong and A-share innovative pharmaceutical sectors saw significant gains, with the Hang Seng Innovative Drug ETF rising by 4.08% and the Hong Kong Stock Connect Medical ETF increasing by 4.25% [3] - Notable individual stock performances included 3SBio (01530.HK) reaching a peak of 22.5 HKD, just shy of its historical high, and a 260% increase in its stock price since February [3] - The A-share innovative drug index rose by 31.5% and the Hong Kong innovative drug index surged by 61.54% since April 9, with several stocks doubling in value [4] Group 2: Catalysts for Growth - The surge in innovative drug stocks is attributed to multiple factors, including recent approvals for 11 innovative drugs from eight companies and promising clinical data for major diseases [5] - The upcoming 2025 ASCO annual meeting will feature 73 research studies from China, a 30% increase from the previous year [5] Group 3: Long-term Positive Factors - Many leading companies are approaching breakeven points, with significant revenue growth reported, particularly for Ascentage Pharma (332.31% growth) [7][8] - The overseas licensing deals have seen substantial increases, with a record-breaking deal of 6.05 billion USD for 3SBio's drug rights to Pfizer [9] - The overall licensing-out transactions in the innovative drug sector have surged, with 41 transactions in Q1 2024 alone, totaling 36.93 billion USD [9] Group 4: Policy Support - Recent policy changes are favorable for innovative drug companies, including optimized centralized procurement policies and increased support for innovative drugs in government reports [10] - The 2024 government work report includes 38 new innovative drugs in the medical insurance catalog, the highest ever, with plans for further optimization in 2025 [10] Group 5: Market Outlook - The valuation of the pharmaceutical sector remains relatively safe compared to other growth industries, with a current TTM P/E ratio of 27.1 times [11] - Some analysts suggest that the innovative drug sector is transitioning from following to leading in the global market, indicating a new era for domestic innovation [11] - However, there are concerns about potential short-term volatility due to rapid price increases and profit-taking by investors [11]

Group 1 - The report emphasizes the active overseas commercialization of innovative drugs, with several domestic innovative drugs presenting excellent data at the ASCO conference, highlighting ongoing business development (BD) opportunities and clinical progress of key pipelines [3][39]. - Key companies such as BeiGene, Innovent Biologics, and others are expected to achieve significant milestones, including BeiGene's projected non-GAAP operating profit of $45 million in 2024 and a positive cash flow in 2025 [3][4]. - The report notes that the Hong Kong pharmaceutical sector has shown strong performance, with the Hang Seng Healthcare Index rising approximately 42% year-to-date, driven by the successful execution of BD transactions and the internationalization of domestic innovative drugs [14][39]. Group 2 - The report outlines the financial forecasts for key companies, indicating that BeiGene's revenue is expected to grow from 36.69 billion HKD in 2025 to 44.36 billion HKD in 2026, with a significant increase in net profit from 1.25 billion HKD to 4.56 billion HKD [4]. - The innovative drug sector is projected to see a revenue increase of 30% year-on-year in 2024, with total revenue reaching 71.88 billion HKD, while the overall loss for innovative drug companies is expected to narrow by 29% [35][36]. - The report highlights the increasing number of license-out transactions, with 81 transactions in 2024 totaling $45 billion, reflecting a 28% year-on-year growth, and a notable deal between 3SBio and Pfizer involving a $1.25 billion upfront payment [43][44]. Group 3 - The report indicates that the pharmaceutical sector is undergoing a transformation, with leading companies like Hansoh Pharmaceutical and China National Pharmaceutical Group achieving revenue growth rates of 21% and 10% respectively in 2024 [35]. - The medical services sector is facing pressure due to the impact of healthcare insurance policies and macroeconomic conditions, which may affect growth in consumer medical services [39]. - The CXO sector is showing signs of improvement, with a focus on the recovery of orders, indicating a potential rebound in performance [39]. Group 4 - The report provides a comparative analysis of valuations, noting that the overall valuation of Hong Kong pharmaceuticals is lower than that of A-share and overseas pharmaceuticals, with a median PE of 15x for Hong Kong compared to 24.7x for A-share [12][14]. - The report highlights the significant performance disparity among sub-sectors, with innovative drugs and pharma benefiting from ongoing BD transactions and a favorable valuation correction, while medical services are under pressure [18][39]. - The report also mentions the increasing trend of dual-listed pharmaceutical companies, with the number rising from 5 in 2017 to 20 currently, indicating a growing interest in the Hong Kong market [23].

Core Viewpoint - Despite the challenges faced during the pandemic, Heng Rui Medicine has shown resilience and potential for growth, particularly with its recent transition to the Hong Kong stock market, which may signal a new chapter in its international expansion strategy [2][4][7]. Group 1: Company Performance and Strategy - Heng Rui Medicine, known as the "first brother" of A-share pharmaceuticals, saw its market value exceed 600 billion RMB in 2021, with a peak stock price increase of 38% during the pandemic [2][4]. - The company has shifted from a focus on generic drugs to innovative drug development, with a strong emphasis on international markets, launching over 20 overseas clinical trials and commercializing products in more than 40 countries [9][12]. - The recent listing on the Hong Kong stock market resulted in a stock price increase of 25.20% on the first day, reflecting investor confidence and the potential for capital to support its innovative drug pipeline [7][11]. Group 2: Financial Performance - In 2022, Heng Rui's revenue was 21.275 billion RMB, with a gross profit margin of 83.6%. By 2023, revenue increased to 22.820 billion RMB, maintaining a gross profit margin of 84.6% [6][10]. - The company's net profit for 2022 was 3.815 billion RMB, which is projected to rise to 4.278 billion RMB in 2023, indicating a growth trajectory in profitability [6][10]. Group 3: Market Position and Future Outlook - Heng Rui Medicine is positioned as a leading player in China's innovative drug sector, aiming for high-quality growth over the next 3-5 years, with the potential to launch 2-3 blockbuster drugs globally [5][9]. - The company is at a critical juncture, where success in international markets could elevate it to the status of a "Chinese version of Roche," while failure could limit its growth to a regional player [9][12]. - The ability to enhance brand influence and overcome international market barriers will be crucial for Heng Rui's future success [14].

由港股创新药带动起来的这一波创新药行情，也使得参与其中的投资者赚得盆满钵满。创新药已然成为 今年私募基金业绩的"胜负手"。当前创新药板块暴涨背后的投资逻辑何在？这一波创新药行情还能走多 远？ 创新药概念股再度大涨，背后有何玄机？ 今日，A股三大指数集体收涨，创新药概念股再度大涨，舒泰神、常山药业等10多只个股涨停。拉长时 间看，舒泰神、一品红等创新药个股年内涨幅已超200%，不少个股股价已翻倍。 数据显示，A股创新药指数年内上涨24.56%，港股恒生创新药指数年内更是大涨超60%。 每经记者｜杨建 每经编辑｜肖芮冬 今年以来，A股市场热点不断，上半年市场炒过机器人、AI、核聚变等科技板块，近期创新药行情集中 爆发。 对于高歌猛进的创新药行情还能走多远，是目前市场关注的焦点。易小斌表示，创新药的行情还是具有 一定的延续性，目前医药（中信一级）指数的涨幅为10.77%，但幅度并不惊人，之所以给人感觉涨势 迅猛，更多的还是结构性行情的体现。生物医药等个股强势突破，而还有超过120家的医药公司年初至 今涨幅为负。更为重要的是，医药类上市公司的基本面在经过集采等多重因素的影响后，基本面逐渐得 到改善，新产品层出不穷，研 ...

Market Overview - The market experienced a day of upward volatility, with the ChiNext Index leading the gains. The Shanghai Composite Index rose by 0.43%, the Shenzhen Component increased by 0.65%, and the ChiNext Index climbed by 1.07% [1] - Over 4,100 stocks in the market saw an increase, with total trading volume reaching 1.29 trillion yuan, an increase of 134.4 billion yuan compared to the previous trading day [1] Sector Performance - The innovative drug sector, along with football concepts, rare earth permanent magnets, and controllable nuclear fusion, saw significant gains, while a few sectors like precious metals experienced declines [1] - The innovative drug sector had a notable performance, with many stocks hitting the daily limit. The sector's stocks showed a strong upward trend, contributing to the overall market strength [3][4] Innovative Drug Sector Insights - The innovative drug sector's surge is attributed to recent adjustments and a renewed interest in the sector, with 20 out of 197 component stocks rising by over 10% [4] - The external authorization trading and related expectations have been identified as key drivers for the current innovative drug market rally, with a record high in business development (BD) transactions [5] - In the first five months of 2025, China's innovative drug external authorization trading reached 45.5 billion USD, accounting for over 30% of the global total [5] Market Sentiment and Index Levels - The Shanghai Composite Index briefly surpassed the 3,400-point mark but closed at 3,399.77, indicating a need for stronger momentum to maintain above this psychological level [6][8] - The last three minutes of trading saw attempts to push the index higher, but it was primarily pressured by major stocks in sectors like coal, banking, and insurance [7][8] Financial Sector Developments - The financial sector, particularly securities firms, showed significant activity, with the "Hui Jin" system's brokerages leading the charge. This could signal a new wave of mergers and acquisitions in the securities industry [11] - Analysts suggest that the performance of the financial sector will be crucial for the index's ability to break through resistance levels, with upcoming financial policy announcements expected to influence market sentiment [12]

Group 1: Market Overview - The Shanghai Composite Index has returned to 3,400 points, and the Hang Seng Tech Index is approaching a technical bull market, with the CRO and innovative drug sectors leading in gains [1] - Multiple Hong Kong innovative drug ETFs have seen year-to-date gains exceeding 50%, leading the ETF market [1][3] Group 2: Innovative Drug Sector Performance - After four years of deep correction, the Hong Kong innovative drug sector is experiencing a significant rebound, driven by the international expansion of innovative drugs [6] - The number of domestic new drugs selected for the 2025 ASCO annual meeting has reached a new high, with 74 research abstracts, including 34 oral presentations and 32 rapid oral presentations [6] - The market is showing considerable divergence regarding the current enthusiasm for the innovative drug sector, with some experts expressing caution [6][10] Group 3: IPO Activity in Hong Kong - The Hong Kong IPO market is currently very active, with 74 new stocks expected to be listed from June 8, 2024, to June 8, 2025, and 43 of these stocks trading above their issue prices [13] - The total amount raised through IPOs in Hong Kong has exceeded 776 billion HKD in the first five months of the year, a more than sevenfold increase compared to the same period last year [13] Group 4: Investment Sentiment - International investors are showing improved sentiment towards Chinese stocks, particularly in the "new consumption" and technology sectors [11] - Analysts suggest that the scarcity of assets in the Hong Kong market, particularly in sectors like the internet, new consumption, and innovative drugs, is contributing to its attractiveness [13]